Literature DB >> 10905662

MEFV mutations in multiplex families with familial Mediterranean fever: is a particular genotype necessary for amyloidosis?

M Tekin1, F Yalçinkaya, N Cakar, N Akar, M Misirlioğlu, H Taştan, N Tümer.   

Abstract

Familial Mediterranean fever (FMF) is an autosomal recessive disease. It is characterized by recurrent febrile episodes in association with peritonitis, pleuritis, and arthritis. Progressive systemic amyloidosis is the most important complication of FMF that inevitably leads to chronic renal failure. Recently, the gene for FMF, MEFV, has been cloned and four missense mutations have been described: M694V, M680I, V726A, and M694I. Initial studies have suggested that the presence of the M694V mutation carries a significant risk for the development of amyloidosis. In this study, we present seven families, in which at least two individuals have been diagnosed with FMF and at least one with amyloidosis. Among 18 individuals, in whom molecular testing was performed for the four aforementioned mutations, ten had amyloidosis. None of these ten individuals was found to be homozygous for the M694V mutation. In three families, there were two sibs with amyloidosis. None of the sib-pairs with amyloidosis was found to have the same genotype. There were two or more sibs with the same genotype in four families. Only one sib from each family developed amyloidosis in these families. These results provide evidence that FMF patients without the M694V mutation are also at risk for the development of amyloidosis. Particular mutations themselves do not appear to be sufficient to explain the occurrence of amyloidosis in all cases with FMF.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10905662     DOI: 10.1034/j.1399-0004.2000.570605.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  8 in total

1.  Sacroiliitis in familial Mediterranean fever and seronegative spondyloarthropathy: importance of differential diagnosis.

Authors:  Birol Balaban; Evren Yasar; Ahmet Ozgul; Kemal Dincer; Tunc Alp Kalyon
Journal:  Rheumatol Int       Date:  2005-02-12       Impact factor: 2.631

Review 2.  Familial Mediterranean fever.

Authors:  Fatos Onen
Journal:  Rheumatol Int       Date:  2005-11-10       Impact factor: 2.631

3.  As a new inflammatory marker for familial Mediterranean fever: neutrophil-to-lymphocyte ratio.

Authors:  Ahmet Ahsen; Memnune Sena Ulu; Seref Yuksel; Kasım Demir; Mukremin Uysal; Mujgan Erdogan; Gursel Acarturk
Journal:  Inflammation       Date:  2013-12       Impact factor: 4.092

4.  The contribution of genotypes at the MICA gene triplet repeat polymorphisms and MEFV mutations to amyloidosis and course of the disease in the patients with familial Mediterranean fever.

Authors:  Nuran Turkcapar; Timur Tuncali; Sim Kutlay; Basak Yalcin Burhan; Gulay Kinikli; Sehsuvar Erturk; Murat Duman
Journal:  Rheumatol Int       Date:  2006-11-11       Impact factor: 2.631

5.  E148Q is a disease-causing MEFV mutation: a phenotypic evaluation in patients with familial Mediterranean fever.

Authors:  R Topaloglu; F Ozaltin; E Yilmaz; S Ozen; B Balci; N Besbas; A Bakkaloglu
Journal:  Ann Rheum Dis       Date:  2004-09-30       Impact factor: 19.103

6.  Amyloidosis in familial Mediterranean fever patients: correlation with MEFV genotype and SAA1 and MICA polymorphisms effects.

Authors:  Myrna Medlej-Hashim; Valérie Delague; Eliane Chouery; Nabiha Salem; Mohammed Rawashdeh; Gérard Lefranc; Jacques Loiselet; André Mégarbané
Journal:  BMC Med Genet       Date:  2004-02-10       Impact factor: 2.103

Review 7.  Protein folding pathology in domestic animals.

Authors:  Erik Gruys
Journal:  J Zhejiang Univ Sci       Date:  2004-10

8.  A molecular analysis of familial Mediterranean fever disease in a cohort of Turkish patients.

Authors:  Munis Dundar; Aslihan Kiraz; Elif Funda Emirogullari; Ccedil Etin Saatci; Serpil Taheri; Mevlut Baskol; Seher Polat; Yusuf Ozkul
Journal:  Ann Saudi Med       Date:  2012 Jul-Aug       Impact factor: 1.526

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.